[{"id":"fa453285-78f4-4385-843c-3139f84fb779","acronym":"","url":"https://clinicaltrials.gov/study/NCT02260661","created_at":"2021-01-18T10:37:18.225Z","updated_at":"2024-07-02T16:37:28.613Z","phase":"Phase 1","brief_title":"Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT02260661","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • AZD8835"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 07/01/2016","study_completion_date":" 07/01/2016","last_update_posted":"2016-10-10"}]